# EDGAR Filing Document

**Accession Number:** 0001326205
**File Stem:** 0001185185-25-000997
**Filing Date:** 2025-8
**Character Count:** 107259
**Document Hash:** f141ea74fefd45df685c71223707bf6b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001185185-25-000997.hdr.sgml**: 20250814

**ACCESSION NUMBER**: 0001185185-25-000997

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 98

**CONFORMED PERIOD OF REPORT**: 20250630

**FILED AS OF DATE**: 20250814

**DATE AS OF CHANGE**: 20250814

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** IGC Pharma, Inc.
- **CENTRAL INDEX KEY:** 0001326205
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 202760393
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 0331

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-32830
- **FILM NUMBER:** 251218659

**BUSINESS ADDRESS:**
- **STREET 1:** 10224 FALLS ROAD
- **CITY:** POTOMAC
- **STATE:** MD
- **ZIP:** 20854
- **BUSINESS PHONE:** 301-983-0998

**MAIL ADDRESS:**
- **STREET 1:** 10224 FALLS ROAD
- **CITY:** POTOMAC
- **STATE:** MD
- **ZIP:** 20854

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** India Globalization Capital, Inc.
- **DATE OF NAME CHANGE:** 20050505

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 10-Q**

☑ **Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**For the quarterly period ended June 30, 2025**

☐ **Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Commission file number: <u>001-32830</u>**

![](image_001.jpg)

**<u>IGC PHARMA, INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Maryland** | **20-2760393** |
| (State or other jurisdiction<br> of incorporation or organization) | (I.R.S. Employer <br> Identification No.) |
| **10224 Falls Road, Potomac, Maryland** | **20854** |
| (Address of principal executive offices) | (Zip Code) |

---

**<u>(301) 983-0998</u>**

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share IGC | NYSE American LLC |

---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑ Yes ☐ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).☑ Yes ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☑ Smaller reporting company ☑ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☑ No

90,809,112 shares of our common stock were outstanding as of July 28, 2025.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

**IGC PHARMA, INC.** 

**FORM 10-Q**

**FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2025**

**<u>**Table of Contents**</u>**

---

| | | |
|:---|:---|:---|
|  |  | **Page** |
| **PART I. FINANCIAL INFORMATION** | **PART I. FINANCIAL INFORMATION** | **PART I. FINANCIAL INFORMATION** |
| Item 1. | [Financial Statements](#a_002) | 4 |
|  | [Condensed Consolidated Balance Sheets](#a_003) | 4 |
|  | [Condensed Consolidated Statements of Operations and Comprehensive Loss](#a_004) | 5 |
|  | [Condensed Consolidated Statements of Changes in Shareholder's Equity](#a_005) | 6 |
|  | [Condensed Consolidated Statements of Cash Flows](#a_006) | 7 |
|  | [Notes to Condensed Consolidated Financial Statements](#a_007) | 8 |
| Item 2. | [Management's Discussion and Analysis of Financial Condition and Results of Operations](#a_008) | 21 |
| Item 3. | [Quantitative and Qualitative Disclosures About Market Risk](#a_009) | 27 |
| Item 4. | [Controls and Procedures](#a_010) | 27 |
| **PART II. OTHER INFORMTION** | **PART II. OTHER INFORMTION** | **PART II. OTHER INFORMTION** |
| Item 1. | [Legal Proceedings](#a_012) | 28 |
| Item 1A. | [Risk Factors](#a_013) | 29 |
| Item 2. | [Unregistered Sales of Equity Securities and Use of Proceeds](#a_014) | 29 |
| Item 3. | [Defaults Upon Senior Securities](#a_015) | 29 |
| Item 4. | [Mine Safety Disclosures](#a_016) | 29 |
| Item 5. | [Other Information](#a_017) | 29 |
| Item 6. | [Exhibits](#a_018) | 30 |
| **[SIGNATURES](#a_019)** | **[SIGNATURES](#a_019)** | 31 |

---

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**FORWARD-LOOKING STATEMENTS**

*This Quarterly Report on Form 10-Q and the documents incorporated herein by reference contain "forward-looking statements." Additionally, we, or our representatives, may, from time to time, make other written or verbal forward-looking statements and discuss plans, expectations, and objectives regarding our business, financial condition, and results of operations. Without limiting the foregoing, statements that are in the future tense, and all statements accompanied by terms such as "believe," "hope," "potential," "project," "expect," "trend," "estimate," "forecast," "assume," "intend," "plan," "target," "anticipate," "outlook, "preliminary," "will likely result," "will continue," and variations of them and similar terms are intended to be forward-looking statements" as defined by federal securities laws. Such statements are based on currently available information, which management has assessed but which is dynamic and subject to rapid change due to risks and uncertainties that affect our business.* 

 

*For the next several years, we believe our success is highly correlated with the outcome of our clinical trials and, secondarily, with the sale of our products and services. The Company may not be able to complete human trials on our investigational drug candidates, or, once conducted, the results of human trials may not be favorable or as anticipated or may reflect a lack of efficacy in humans or animals. Precautions, including social distancing and travel restrictions, among others, could lead to delays or expenses greater than anticipated or projected. Failure or delay with respect to any of the above factors could have a material adverse effect on our business, future results of operations, stock price, and financial condition.* 

 

*Our projections and investments anticipate certain regulatory changes and stable pricing, which may not hold out over the next several years. We may not be able to protect our intellectual property adequately or receive patents. We may not receive regulatory approval for our products or trials. The patent applications we have licensed may not be granted by the United States Patent and Trademark Office ("USPTO"), even if the Company is in full compliance with USPTO requirements. We may not have adequate resources, including financial resources, to successfully conduct all requisite clinical trials, to bring a product based on the above-referenced patented formulations to market, or to pay applicable maintenance fees over time. We may not be able to successfully commercialize our products even if they are successful and receive regulatory approval, including, but not limited to, based on the Food and Drug Administration's ("FDA") current position on hemp and hemp-based products. Failure or delay with respect to any of the factors above could have a material adverse effect on our business, future results of operations, stock price, and financial condition.* 

 

*This document also contains statements that are not approved by the FDA, including but not limited to the statements on hemp and hemp extracts and their potential efficacy on humans and animals. While these statements and claims are intended to be in compliance with federal and state laws, we cannot guarantee such compliance.* 

 

*We caution you not to place undue reliance on forward-looking statements, which are based upon assumptions, expectations, plans, and projections subject to risks and uncertainties, including those, if any, identified in the "Risk Factors" set forth in this report or in our annual report on Form 10-K for the fiscal year ended March 31, 2025, filed with the Securities and Exchange Commission ("SEC") on June 27, 2025 and other documents that we subsequently file with the SEC that update, supplement or supersede such information, which may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Forward-looking statements speak only as of the date when they are made. Except as required by federal securities law, we do not undertake any obligation to update forward-looking statements to reflect events, circumstances, changes in expectations, or the occurrence of unanticipated events after the date of those statements.* 

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**PART I** – **FINANCIAL INFORMATION**

**Item 1. Financial Statements** 

**IGC Pharma, Inc.**

**CONDENSED CONSOLIDATED BALANCE SHEETS**

***(in thousands, except share data)***

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **June 30, <br> 2025 <br> ($)** | **March 31, <br> 2025<br> ($)** |
| **ASSETS** | | |
| **Current assets:** | | |
| Cash and cash equivalents | 454 | 405 |
| Accounts receivable, net | 87 | 34 |
| Inventory | 1349 | 1360 |
| Asset held for sale |  | 702 |
| Deposits and advances | 212 | 395 |
| Operating lease asset-current | 51 | - |
| **Total current assets** | **2153** | **2896** |
| **Non-current assets:** |  |  |
| Intangible assets, net | 1997 | 1852 |
| Property, plant, and equipment, net | 3097 | 3220 |
| Claims and advances | 680 | 681 |
| Operating lease asset | 16 | 98 |
| **Total non-current assets** | **5790** | **5851** |
| **Total assets** | **7943** | **8747** |
| **<u>LIABILITIES AND STOCKHOLDERS' EQUITY</u>** |  |  |
| **Current liabilities:** |  |  |
| Accounts payable | 933 | 883 |
| Accrued liabilities and others | 792 | 1374 |
| **Total current liabilities** | **1725** | **2257** |
| **Non-current liabilities:** |  |  |
| Long-term loans | 133 | 134 |
| Other liabilities |  | 16 |
| Operating lease liability | 7 | 10 |
| **Total non-current liabilities** | **140** | **160** |
| **Total liabilities** | **1865** | **2417** |
| **Commitments and Contingencies – See Note 12** |  |  |
| **Stockholders' equity:** |  |  |
| Preferred stock, $0.0001 par value: authorized 1,000,000 shares, no shares issued or outstanding as of June 30, 2025, and March 31, 2025. |  |  |
| Common stock and additional paid-in capital, $0.0001 par value: 150,000,000 shares authorized; 84,141,405 and 80,878,058 shares issued and outstanding as of June 30, 2025, and March 31, 2025, respectively. | 131920 | 130570 |
| Accumulated other comprehensive loss | (3499) | (3496) |
| Accumulated deficit | (122343) | (120744) |
| **Total stockholders' equity** | **6078** | **6330** |
| **Total liabilities and stockholders' equity** | **7943** | **8747** |

---

The accompanying notes should be read in connection with these Condensed Consolidated Financial Statements.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**IGC Pharma, Inc.**

**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**

***(in thousands, except loss per share and share data)***

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Three months ended <br> June 30,** | **Three months ended <br> June 30,** |
|  | **2025<br> ($)** | **2024<br> ($)** |
| Revenue | 328 | 272 |
| Cost of revenue | (174) | (109) |
| **Gross profit** | **154** | **163** |
| Selling, general, and administrative expenses | (1208) | (1670) |
| Research and development expenses | (851) | (889) |
| **Operating loss** | **(1905)** | **(2396)** |
| Other income, net | 306 | 18 |
| **Loss before income taxes** | **(1599)** | **(2378)** |
| Income tax expense/benefit |  |  |
| **Net loss attributable to common stockholders** | **(1599)** | **(2378)** |
| Foreign currency translation adjustments | (3) | (3) |
| **Comprehensive loss** | **(1602)** | **(2381)** |
| **Net loss per share attributable to common stockholders:** |  |  |
| Basic and diluted | $(0.02) | $(0.03) |
| Weighted-average number of shares used in computing loss per share amounts: | 83027117 | 72813538 |

---

The accompanying notes should be read in connection with these Condensed Consolidated Financial Statements.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**IGC Pharma, Inc.**

**CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS**' **EQUITY**

***(in thousands)***

**(Unaudited)**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Number of<br> Common<br> Shares** | **Common<br> Stock and<br> Additional<br> Paid in<br> Capital <br> ($)** | **Accumulated<br> Deficit<br> ($)** | **Accumulated<br> Other<br> Comprehensive<br> Loss<br> ($)** | **Total <br> Stockholders'<br> Equity <br> ($)** |
| **Balances as of March 31, 2024** | **66691** | **124409** | **(113665)** | **(3423)** | **7321** |
| Common stock-based compensation & expenses, net |  | 433 |  |  | 433 |
| Share money received but not allotted |  |  |  |  |  |
| Issuance of common stock through offering (net of expenses) | 8945 | 2507 |  |  | 2507 |
| Cancellation/forfeiture of shares |  |  |  |  |  |
| Common stock subscribed |  |  |  |  |  |
| Net loss |  |  | (2378) |  | (2378) |
| Foreign currency translation | - | - | - | (3) | (3) |
| **Balances as of June 30, 2024** | **75636** | **127349** | **(116043)** | **(3426)** | **7880** |
| **Balances as of March 31, 2025** | **80878** | **130570** | **(120744)** | **(3496)** | **6330** |
| Common stock-based compensation & expenses, net |  | 498 |  |  | 498 |
| Share money received but not allotted |  | 13 |  |  | 13 |
| Issuance of common stock through offering (net of expenses) | 3263 | 839 |  |  | 839 |
| Cancellation/forfeiture of shares |  |  |  |  |  |
| Common stock subscribed |  |  |  |  |  |
| Net loss |  |  | (1599) |  | (1599) |
| Foreign currency translation | - | - | - | (3) | (3) |
| **Balances as of June 30, 2025** | **84141** | **131920** | **(122343)** | **(3499)** | **6078** |

---

The accompanying notes should be read in connection with these Condensed Consolidated Financial Statements.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**IGC Pharma, Inc.**

**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

***(in thousands)***

**(Unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Three months ended <br> June 30,** | **Three months ended <br> June 30,** |
|  | **2025<br> ($)** | **2024<br> ($)** |
| **Cash flows from operating activities:** |  |  |
| **Net loss** | **(1599)** | **(2378)** |
| *Adjustment to reconcile net loss to net cash:* |  |  |
| Depreciation and amortization | 141 | 162 |
| Common stock-based compensation and expenses, net | 452 | 402 |
| Other non-cash items | (24) |  |
| *Changes in:* |  |  |
| Accounts receivable, net | (53) | 11 |
| Inventory | 11 | 30 |
| Deposits and advances | 183 | (118) |
| Claims and advances |  |  |
| Accounts payable | 51 | (2) |
| Accrued and other liabilities | (599) | 151 |
| Operating lease asset | 32 | 5 |
| Operating lease liability | (2) | (15) |
| **Net cash used in operating activities** | **(1407)** | **(1752)** |
| **Cash flow from investing activities:** |  |  |
| Purchase of property, plant, and equipment | (8) | (38) |
| Sale of property, plant, and equipment | 702 |  |
| Acquisition and development of intangible assets | (114) | (93) |
| **Net cash provided by (used in) investing activities** | **580** | **(131)** |
| **Cash flows from financing activities:** |  |  |
| Net proceeds from the issuance of common stock | 852 | 2508 |
| Repayment of a long-term loan | (1) | (1) |
| **Net cash provided by financing activities** | **851** | **2507** |
| Effects of exchange rate changes on cash and cash equivalents | 25 | 2 |
| **Net increase in cash and cash equivalents** | **49** | **626** |
| Cash and cash equivalents at the beginning of the period | 405 | 1198 |
| **Cash and cash equivalents at the end of the period** | **454** | **1824** |
| **Supplementary information:** |  |  |
| Interest paid | **1** | 1 |
| ***Non-cash item:*** |  |  |
| Profit on the sale of Asset held for sale | 24 |  |

---

The accompanying notes should be read in connection with these Condensed Consolidated Financial Statements.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**IGC Pharma, Inc.**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**THREE MONTHS ENDED JUNE 30, 2025**

**(in thousands, except for share data and loss per share, unaudited)**

*Unless the context requires otherwise, all references in this report to "IGC," "IGC Pharma," "the Company," "we," "our," and "us" refer to IGC Pharma, Inc., together with our subsidiaries and beneficially owned subsidiary. Our public filings with the Securities and Exchange Commission, the "SEC," are available on www.sec.gov. The information contained on our various websites, including www.igcpharma.com, is not incorporated by reference in this report, and you should not consider such information to be a part of this report. We exclude our investments and minority non-controlling interests, and any information provided by them is not incorporated by reference in this report, and you should not consider such information to be a part of this report.* 

**NOTE 1** – **BUSINESS DESCRIPTION**

**Overview**

IGC Pharma, a clinical-stage pharmaceutical company attempting to leverage AI to develop potentially innovative treatments for Alzheimer's disease (AD), metabolic disorder, and related neurodegenerative conditions. IGC Pharma is committed to transforming patient care by seeking to offer faster-acting and more effective solutions. The Company's research and development efforts are centered on addressing some of the most challenging and underserved symptoms of Alzheimer's, with the lead investigational candidate, IGC-AD1, positioned at the forefront of this strategy. It is designed to treat agitation in Alzheimer's dementia, a common and difficult-to-manage neuropsychiatric symptom that significantly impacts millions of patients' well-being and caregiver burden.

Our mission is to improve the lives of individuals affected by Alzheimer's disease by addressing both its symptoms and the disease. Our near-term focus is on advancing IGC-AD1, our lead drug candidate currently in Phase 2 clinical trials targeting agitation in Alzheimer's patients. We are also investing in our early-stage pipeline of investigational therapies and exploring Artificial Intelligence (AI) powered models designed to identify early markers of Alzheimer's. We believe that combining scientific innovation with operational execution, including leveraging our internal contract research organization, positions us to efficiently advance our pipeline toward commercialization, although there can be no assurance thereof. Our long-term strategy is to build a portfolio of differentiated therapies that not only address symptomatic needs but also target disease-modifying mechanisms, thereby creating sustainable value for patients, caregivers, and shareholders.

**Business Organization**

As of June 30, 2025, the Company had the following operating subsidiaries: Techni Bharathi Private Limited (TBL), HH Processors, LLC, IGC Pharma IP, LLC, IGC Pharma, LLC, SAN Holdings, LLC, Hamsa Biopharma India Pvt. Ltd. and Colombia-based beneficially owned subsidiary IGC Pharma SAS. The Company's fiscal year is the 52- or 53-week period that ends on March 31. The Company's principal office is in Maryland, established in 2005. Additionally, the Company has offices in Washington state, Colombia, South America, and India. The Company's filings are available on www.sec.gov.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**NOTE 2** – **SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Basis of presentation**

The accompanying condensed consolidated Balance Sheet as of June 30, 2025, and March 31, 2025, condensed consolidated statements of operations for the three months ended June 30, 2025, and 2024, and condensed consolidated statements of cash flows for the three months ended June 30, 2025, and 2024, are unaudited. The consolidated balance sheet as of March 31, 2025, has been derived from audited financial statements, and the accompanying as of June 30, 2025 unaudited condensed consolidated financial statements (interim statements) of the Company have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) as determined by the Financial Accounting Standards Board (the FASB) within its Accounting Standards Codification (ASC) and under the rules and regulations of the SEC.

Accordingly, they do not include all the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments and disclosures necessary for a fair presentation of these interim statements have been included. The results reported in these interim statements are not necessarily indicative of the results that may be reported for the entire year. These interim statements should be read in conjunction with the Company's audited consolidated financial statements for the fiscal year ended March 31, 2025 (Fiscal 2025) contained in the Company's Form 10-K for Fiscal 2025, filed with the SEC on June 27, 2025, specifically in Note 2 to the consolidated financial statements.

**Principles of consolidation**

The interim statements include the consolidated accounts of the Company and its subsidiaries. Intercompany accounts and transactions have been eliminated. In the opinion of the Company's management, the interim statements reflect all adjustments, which are normal and recurring in nature, necessary for fair financial statement presentation. Transactions between the Company and its subsidiaries are eliminated in the consolidated financial statements.

**Presentation and functional currencies** 

IGC operates in the U.S., India and Colombia, and a substantial portion of the Company's financials are denominated in the Indian Rupee (INR), or the Colombian Peso (COP). As a result, changes in the relative values of the U.S. Dollar (USD), the INR, or the COP affect our financial statements.

The accompanying financial statements are reported in USD. The INR and COP are the functional currencies for certain subsidiaries of the Company. The translation of the functional currencies into USD is performed for assets and liabilities using the exchange rates in effect at the balance sheet date and for revenues and expenses using average exchange rates prevailing during the reporting periods. Adjustments resulting from the translation of functional currency financial statements to the reporting currency are accumulated and reported as other comprehensive income/(loss), a separate component of shareholders' equity. Transactions in currencies other than the functional currency during the year are converted into the functional currency at the applicable rates of exchange prevailing when the transactions occurred. Transaction gains and losses are recognized in the consolidated statements of operations.

**Going Concern**

The Company assesses and determines its ability to continue as a going concern in accordance with the provisions of ASC Subtopic 205-40, "*Presentation of Financial Statements*—*Going Concern*", which requires the Company to evaluate whether there are conditions or events that raise substantial doubt about its ability to continue as a going concern.

The Company is currently in a clinical trial stage and, thus, has not yet achieved profitability. The Company expects to continue to incur significant operating and net losses and negative cash flows from operations in the near future. On June 24, 2025, the Company entered into an amendment to extend its existing Credit Agreement of $12 million with the Lender, effective June 24, 2025. The amendment extends the term of the Credit Agreement, which was set to expire, under the same terms and conditions as previously disclosed on the Company's Current Report on Form 8-K filed with the Securities Exchange Commission on August 2, 2024, with the exception of i) a reduction in the facility fees from $84,000 to $48,000 and ii) interest, calculated according to the interest rate mentioned in the Certificate of Deposit, as the case may be, plus an applicable margin of 1.2%, instead of 1%. All other material terms of the Loan Agreement remain unchanged.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

The Company estimates that its current cash and cash equivalents balance, with the working capital and investments, and with an available overdraft facility of $12 million from O-Bank, is sufficient to support operations for at least the next twelve months following the date these consolidated financial statements and footnotes were issued. These estimates are based on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects.

**Accounts receivable**

We make estimates of the collectability of our accounts receivable by analyzing historical payment patterns, customer concentrations, customer creditworthiness, and current economic trends. If the financial condition of a customer deteriorates, additional allowances may be required. We had $87 thousand of accounts receivable, net of provision for the doubtful debt of $13 thousand as of June 30, 2025, as compared to $34 thousand of accounts receivable, net of provision for the doubtful debt of $12 thousand as of March 31, 2025.

**Software Development Costs**

The Company is developing two proprietary software platforms intended to be commercialized: -

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. A **clinical data management platform** designed for the collection, analysis, and real-time monitoring of clinical trial data; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. An **MINT- AD - AI-driven diagnostic and treatment personalization platform** aimed at assisting in the early detection of Alzheimer's disease and providing data-informed therapeutic suggestions.

In accordance with **ASC 985-20**, *Software to Be Sold, Leased, or Marketed*, the Company capitalizes development costs incurred after technological feasibility has been established and before the software is available for general release. Costs incurred during the research, planning, or preliminary design phase are expensed as incurred.

Capitalized costs include direct labor, third-party development services, cloud computing infrastructure directly related to model development and deployment and associated overhead. These costs are amortized on a straight-line basis over their estimated useful lives, typically **five to ten years**, beginning when the software is ready for its intended commercial use.

During the quarter ended June 30, 2025, the Company capitalized approximately $144 thousand in software development costs. For more information, please refer to Note 5, "Intangible Assets".

**Loss per share**

The computation of basic loss per share for the three months ended June 30, 2025, excludes potentially dilutive securities of approximately 14 million shares, which includes share options, unvested shares such as restricted shares awards and units, granted to directors, employees, non-employees, and advisors, and shares from the conversion of outstanding units, if any because their inclusion would be anti-dilutive.

The weighted average number of shares outstanding for the three months ended June 30, 2025, and 2024, used for the computation of basic earnings per share (EPS) is 83,027,117 and 72,813,538, respectively. Due to the loss incurred by the Company during the three months ended June 30, 2025, and 2024, all the potential equity shares are anti-dilutive, and accordingly, the fully diluted EPS is equal to the basic EPS.

**Cybersecurity**

We have a cybersecurity policy in place and have taken cybersecurity measures to safeguard against hackers, however, there can be no assurance thereof. During the three months ended June 30, 2025, there were no significant cybersecurity breaches.

**Revenue Recognition**

The Company recognizes revenue under ASC 606, *Revenue from Contracts with Customers* (ASC 606). The core principle of this standard is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

ASC 606 prescribes a 5-step process to achieve its core principle. The Company recognizes revenue from trading, rental, or product sales as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I. Identify the contract with the customer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;II. Identify the contractual performance obligations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;III. Determine the amount of consideration/price for the transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IV. Allocate the determined amount of consideration/price to the performance obligations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;V. Recognize revenue when or as the performing party satisfies performance obligations.

The consideration/price for the transaction (performance obligation(s)) is determined as per the agreement or invoice (contract) for the services and products in the Life Sciences segment.

In the Life Sciences segment, the revenue from the wellness and lifestyle business is recognized once goods have been sold to the customer and the performance obligation has been completed. In retail sales, we offer consumer products through our online stores. Revenue is recognized when control of the goods is transferred to the customer. This generally occurs upon our delivery to a third-party carrier or to the customer directly. Revenue from white label services is recognized when the performance obligation has been completed and output material has been transferred to the customer.

Net sales disaggregated by significant products and services for the three months ended June 30, 2025, and 2024 are as follows:

---

| | | |
|:---|:---|:---|
|  | **(in thousands) <br> Three months ended June 30,** | **(in thousands) <br> Three months ended June 30,** |
|  | **2025($)** | **2024($)** |
| **Life Sciences segment** |  |  |
| Wellness and lifestyle (1) | 6 | 21 |
| White labeling services (2) | 322 | 251 |
| **Total** | 328 | 272 |

---

(1) Revenue from wellness and lifestyle consists of the sale of products such as gummies, hand sanitizers, bath bombs, lotions, hemp crude extract, hemp isolate, and hemp distillate.

(2) Revenue from white label services consists of rebranding our formulations or the customer's products as per the customer's requirement.

**Recently issued accounting pronouncements**

Changes to U.S. GAAP are established by the FASB in the form of accounting standards updates (ASUs) to the FASB's ASC. The Company considers the applicability and impact of all ASUs. Newly issued ASUs not listed are expected to have no impact on the Company's consolidated financial position and results of operations, because either the ASU is not applicable, or the impact is expected to be immaterial.

**ASU 2023-08, *Intangibles—Goodwill and Other—Crypto Assets (Subtopic 350-60): Accounting for and Disclosure of Crypto Assets***

In December 2023, the Financial Accounting Standards Board (FASB) issued ASU 2023-08, which requires certain crypto assets to be measured at fair value with changes recognized in net income each reporting period. The amendments also require separate presentation of crypto assets measured at fair value and provide for additional disclosure requirements, including a roll-forward of activity, cost basis, and any restrictions. The standard is effective for fiscal years beginning after December 15, 2024, including interim periods within those fiscal years, with early adoption permitted.

The Company's fiscal year beginning April 1, 2025, is subject to the provisions of ASU 2023-08. Although the Company did not hold any crypto assets as of June 30, 2025, subsequent to quarter-end, the management plans a treasury policy permitting investment in digital assets, such as bitcoin and other cryptocurrencies, either directly or through exchange-traded products (ETPs). The Company will adopt ASU 2023-08 in the first quarter of fiscal 2026 and will apply its provisions to any direct holdings of in-scope crypto assets. The Company does not expect the adoption to have a material impact on its consolidated financial statements at the date of adoption, but the presentation of any crypto asset holdings will be subject to the measurement and disclosure requirements of the new standard.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**NOTE 3** – **INVENTORY** 

---

| | | |
|:---|:---|:---|
|  | ***(in thousands)*** | ***(in thousands)*** |
|  | **As of <br> June 30,<br> 2025 <br> ($)** | **As of<br> March 31,<br> 2025 <br> ($)** |
| Raw materials | 1078 | 1104 |
| Finished goods | 271 | 256 |
| **Total** | **1349** | **1360** |

---

During the three months ended June 30, 2025, and 2024, the Company wrote off approximately $3 thousand and $26 thousand of inventory due to abnormal loss, NRV adjustment, product expiration, idle facility expense, freight, handling costs, scrap, and wasted material (spoilage). This charge was recorded in Selling, general, and administrative Expenses.

We capitalize inventory costs related to our investigational drug, provided that management determines there is a potential alternative use for the inventory in future research and development projects or other purposes. As of June 30, 2025, and March 31, 2025, our consolidated balance sheet reported approximately $392 thousand clinical trial-related inventory, respectively.

**NOTE 4** – **DEPOSITS AND ADVANCES**

---

| | | |
|:---|:---|:---|
|  | **(in thousands)** | **(in thousands)** |
|  | **As of <br> June 30,<br> 2025 <br> ($)** | **As of<br> March 31,<br> 2025 <br> ($)** |
| Advances to suppliers and consultants | 17 | 10 |
| Other receivables and deposits | 47 | 43 |
| Prepaid expenses and other current assets | 148 | 342 |
| **Total** | 212 | 395 |

---

The Advances to suppliers and consultants primarily relate to advances to vendors. Prepaid expenses and other current assets include approximately $35 thousand statutory advances as of June 30, 2025, and approximately $49 thousand as of March 31, 2025, respectively.

**NOTE 5** – **INTANGIBLE ASSETS** 

---

| | | |
|:---|:---|:---|
|  | ***(in thousands)*** | ***(in thousands)*** |
|  | **As of <br> June 30,<br> 2025<br> ($)** | **As of<br> March 31,<br> 2025 <br> ($)** |
| ***Amortized intangible assets*** | | |
| Patents | 530 | 530 |
| Other intangibles | 34 | 34 |
| Accumulated amortization | (219) | (205) |
| **Total amortized intangible assets** | **345** | **359** |
| ***Other intangible assets*** |  |  |
| Patents | 645 | 630 |
| Software development cost | 1007 | 863 |
| **Total unamortized intangible assets** | **1652** | **1493** |
| **Total intangible assets** | **1997** | **1852** |

---

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

The value of intangible assets includes the cost of acquiring patent rights, supporting data, and the expense associated with filing various patent applications in different countries, along with granted patents. It also includes acquisition costs related to domains and licenses.

The amortization of patents and patent rights with finite life is up to 20 years, commencing from the date of grant or acquisition. The amortization expense in the three months ended June 30, 2025, and 2024, amounted to approximately $14 thousand and $20 thousand, respectively.

The Company regularly reviews its intangible assets to determine if any intangible asset is other-than-temporarily impaired, which would require the Company to record an impairment charge in the period and concluded that, as of June 30, 2025, there was no impairment.

---

| | |
|:---|:---|
| **Estimated annual amortization expense** | **(in thousands)<br> ($)** |
| For the year ended 2027 | 59 |
| For the year ended 2028 | 65 |
| For the year ended 2029 | 72 |
| For the year ended 2030 | 79 |
| For the year ended 2031 | 87 |

---

**NOTE 6** – **PROPERTY, PLANT, AND EQUIPMENT**

---

| | | | |
|:---|:---|:---|:---|
|  | ***(in thousands, except useful life)*** | ***(in thousands, except useful life)*** | ***(in thousands, except useful life)*** |
|  | **Useful Life<br> (years)** | **As of <br> June 30,<br> 2025 <br> ($)** | **As of<br> March 31,<br> 2025<br> ($)** |
| Buildings and facilities | 25 | 2341 | 2341 |
| Plant and machinery | 5-20 | 3095 | 3087 |
| Computer equipment's | 3 | 186 | 187 |
| Office equipment's | 3-5 | 146 | 144 |
| Furniture and fixtures | 5 | 97 | 96 |
| Vehicles | 5 | 58 | 58 |
| **Total gross value** |  | **5923** | **5913** |
| Less: Accumulated depreciation |  | (2826) | (2693) |
| **Total property, plant, and equipment, net** |  | **3097** | **3220** |

---

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

The depreciation expense in the three months ended June 30, 2025, and 2024 amounted to approximately $127 thousand and $142 thousand, respectively. For more information, please refer to Note 16 – "Segment Information" for the non-current assets other than financial instruments held in the country of domicile and foreign countries.

***Asset Held For Sale***

During the three months ended June 30, 2025, the Company sold the Nagpur land to buyers for a net value of approximately $702 thousand. Ownership and possession of the land were transferred to the buyers.

**NOTE 7** – **LEFT BLANK INTENTIONALLY**

**NOTE 8** – **CLAIMS AND ADVANCES**

---

| | | |
|:---|:---|:---|
|  | **(in thousands)** | **(in thousands)** |
|  | **As of <br> June 30,<br> 2025 <br> ($)** | **As of<br> March 31,<br> 2025<br> ($)** |
| Claims receivable (1) | 680 | 680 |
| Non-current deposits | - | 1 |
| **Total** | 680 | 681 |

---

(1) The claims receivable is due from different vendors. While the Company has initiated collection proceedings internally or with the appropriate authorities, it believes receiving the amount in the next 12 months will be challenging because of the time required for collection proceedings.

**NOTE 9** – **LEFT BLANK INTENTIONALLY**

**NOTE 10** – **ACCRUED LIABILITIES AND OTHERS** 

---

| | | |
|:---|:---|:---|
|  | ***(in thousands)*** | ***(in thousands)*** |
|  | **As of <br> June 30, <br> 2025 <br> ($)** | **As of <br> March 31, <br> 2025 <br> ($)** |
| Compensation and other contributions | 191 | 160 |
| Provision for expenses | 138 | 117 |
| Short-term lease liability | 62 | 94 |
| Other current liability | 401 | 1003 |
| **Total** | **792** | **1374** |

---

Compensation and other contribution-related liabilities consist of accrued salaries to employees. In addition, the provision for expenses includes provision for legal, professional, and marketing expenses. Other current liability also includes statutory payables of approximately $21 thousand and $19 thousand as of June 30, 2025, and March 31, 2025, respectively, and approximately $3 thousand of short-term loans as of June 30, 2025, and March 31, 2025, respectively.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**NOTE 11** – **LOANS AND OTHER LIABILITIES**

*Loan as of June 30, 2025:*

On June 11, 2020, the Company received an Economic Injury Disaster Loan (EIDL) for approximately $150 thousand at an annual interest rate of 3.75%. The Company must pay principal and interest payments of $731 every month beginning June 5, 2021. The SBA will apply each installment payment first to pay interest accrued to the day the SBA receives the payment and will then apply any remaining balance to reduce the principal. All remaining principal and accrued interest is due and payable 30 years from the date of the loan. For the three months ended June 30, 2025, the interest expense and principal payment for the EIDL were approximately $1 thousand and $1 thousand, respectively. For the three months ended June 30, 2024, the interest expense and principal payment for the EIDL were approximately $1 thousand and $1 thousand, respectively. As of June 30, 2025, approximately $133 thousand of the loan is classified as Long-term loans and approximately $3 thousand as Short-term loans.

On June 30, 2023, (the Effective Date), the Company entered into a Master Loan and Security Agreement along with the General Banking Facility Letter (collectively called the Credit Agreement) with O-Bank Co., Ltd., a banking corporation incorporated under the laws of Taiwan, as administrative agent and lender (the Lender) pursuant to which the Borrower may borrow up to $12 million only or the equivalent thereof in other major currencies (the Credit Facility). The Credit Facility under the Credit Agreement contained a maturity date on the first anniversary of the Effective Date. Borrowings under the Loan Agreement will bear interest, calculated according to the interest rate mentioned in the Certificate of Deposit, as the case may be, plus an applicable margin of 1%, and the Borrower shall bear the tax. Interest is due and payable in full by the Borrower on the last business day of each interest period.

On July 29, 2024, the Company entered into an amendment to extend the Credit Agreement with the Lender effective July 8, 2024.

On June 24, 2025, the Company entered into an amendment to the Credit Agreement. The amendment extends the term of the Credit Agreement, which was set to expire, under the same terms and conditions as previously disclosed on the Company's Current Report on Form 8-K filed with the Securities Exchange Commission on August 2, 2024, with the exception of i) a reduction in the facility fees from $84,000 to $48,000 and ii) interest, calculated according to the interest rate mentioned in the Certificate of Deposit, as the case may be, plus an applicable margin of 1.2%, instead of 1% . All other material terms of the Credit Agreement remain unchanged.

*Other Liability:*

---

| | | |
|:---|:---|:---|
|  | **(in thousands)** | **(in thousands)** |
|  | **As of** | **As of** |
|  | **June 30,<br> 2025<br> ($)** | **March 31,<br> 2025 <br> ($)** |
| Statutory reserve |  | 16 |
| **Total** |  | 16 |

---

The statutory reserve is a gratuity reserve for employees in our subsidiaries in India.

**NOTE 12** – **COMMITMENTS AND CONTINGENCIES**

The Company may be involved in legal proceedings, claims, and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. There are no such matters that are deemed material to the condensed consolidated financial statements as of June 30, 2025, except as disclosed in the legal proceedings section below.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

In the U.S., we provide health insurance, life insurance, and a 401(k) plan wherein the Company matches up to 6% of the employee's pre-tax contribution up to a maximum annual amount determined by the IRS. In accordance with applicable laws of foreign countries, the Company provides for gratuity, a defined benefit retirement plan (Gratuity Plan) covering certain categories of employees. The Gratuity Plan provides a lump sum payment to vested employees, at retirement or termination of employment, an amount based on the respective employee's last drawn salary and the years of employment with the Company. In addition, employees receive benefits from a provident fund, a defined contribution plan. The employee and employer each make monthly contributions to the plan as required by the law. The contribution is made to the Foreign Government's funds.

**NOTE 13** – **SECURITIES** 

As of June 30, 2025, the Company was authorized to issue up to 150,000,000 shares of common stock, par value $0.0001 per share, and 84,141,405 shares of common stock were issued and outstanding. The Company is also authorized to issue up to 1,000,000 shares of preferred stock, par value $0.0001 per share, and no preferred shares were issued and outstanding as of June 30, 2025.

Our common stock is listed on the NYSE American (ticker symbol: IGC). This security also trades on the Frankfurt, Stuttgart, and Berlin stock exchanges (ticker symbol: IGS1). The Company also has 91,472 units outstanding that can be separated into common stock. Ten units may be separated into one share of common stock. The unit holders are requested to contact the Company or our transfer agent, Continental Stock Transfer and Trust, to separate their units into common stock.

In the first quarter of Fiscal 2026, the Company entered into Share Purchase Agreements (the 2025 SPAs) with multiple investors, relating to the sale and issuance by our company to investors of an aggregate of 2,803,333 shares of our common stock, for a total purchase price of $841,000, or $0.30 per share, subject to the terms and conditions set forth in the 2025 SPAs. The investments are subject to customary closing conditions, including NYSE approval. As per the 2025 SPAs, the investor received piggyback registration rights subject to certain restrictions. Shares are intended to be exempt from registration under the Securities Act, by virtue of the provisions of Section 4(a)(2) of Securities Act.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**NOTE 14** – **STOCK-BASED COMPENSATION**

As of June 30, 2025, under both the Company's previous 2008 and current 2018 Omnibus Incentive Plans approximately 9.1 million shares of common stock have been issued to employees, non-employees, and advisors. In addition, approximately 8.7 million restricted share units (RSUs) fair valued at approximately $4.7 million with a weighted average value of $0.54 per share, have been granted but not yet issued from different Incentive Plans and Grants.

Additionally, options held by advisors and directors to purchase approximately 5.6 million shares of common stock fair valued at approximately $1.4 million with a weighted average of $0.26 per share, which have been granted but are to be issued over an exercise period between Fiscal 2023 and Fiscal 2028. Options granted and issued before the vesting period are expensed when issued.

The above awards include approximately 4.7 million RSUs and 2 million options granted to employees and directors, which consist of a vesting schedule based entirely on the attainment of either operational milestones (performance conditions) or market conditions, assuming continued employment either as an employee, or director with the Company. The performance-based awards are accounted for upon certification by the Company's management, confirming the probability of achievement of milestones. As of June 30, 2025, the Company's management confirmed that three milestones had been achieved, and the rest were probable to be achieved by March 31, 2028

The options are valued using a Black-Scholes Pricing Model, and Market-based RSUs are valued based on a lattice model, with the following assumptions:

---

| | | |
|:---|:---|:---|
|  | **Granted in<br> Fiscal 2026** | **Granted in<br> Fiscal 2025** |
| Expected life of options | 5 years | 5 years |
| Vested options | 100% | 100% |
| Risk-free interest rate | 3.93% | 5.24% |
| Expected volatility | 171% | 175% |
| Expected dividend yield | Nil | Nil |

---

The expense associated with share-based payments to employees, directors, advisors, and contractors is allocated over the vesting or service period and recognized in the Selling, general, and administrative expenses (including research and development). For the three months ended June 30, 2025, the Company's common stock-based compensation was approximately $452 thousand, which was accounted for in the Selling, general, and administrative expenses (including research and development). In addition, the Company capitalized common stock-based compensation of approximately $46 thousand in software development costs.

For the three months ended June 30, 2024, the Company's common stock-based compensation was approximately $402 thousand, which was accounted for in the Selling, general, and administrative expenses (including research and development). In addition, the Company capitalized common stock-based compensation of approximately $31 thousand in software development costs.

---

| | | |
|:---|:---|:---|
| **Non-vested shares** | **Shares <br> (in thousands)<br> (#)** | **Weighted<br> average<br> grant date<br> fair value<br> ($)** |
| Non-vested shares as of March 31, 2025 | 5796 | 0.64 |
| Granted | 1385 | 0.31 |
| Vested | (679) | 0.31 |
| Cancelled/forfeited | - | - |
| **Non-vested shares as of June 30, 2025** | **6502** | **0.60** |

---

---

| | | | |
|:---|:---|:---|:---|
| **Options** | **Shares<br> (in thousands)<br> (#)** | **Weighted<br> average<br> grant date <br> fair value <br> ($)** | **Weighted<br> average<br> exercise<br> price <br> ($)** |
| Options outstanding as of March 31, 2025 | 3182 | 0.25 | 0.39 |
| Granted | 1600 | 0.27 | 0.30 |
| Vested |  |  |  |
| Cancelled/forfeited | - | - | - |
| **Options outstanding as of June 30, 2025** | **4782** | **0.26** | **0.29** |

---

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

There was a combined unrecognized expense of $2 million related to non-vested shares and share options that the Company expects to be recognized over a life of up to 4 (four) years.

**NOTE 15** – **FAIR VALUE OF FINANCIAL INSTRUMENTS**

As of June 30, 2025, the Company's marketable securities consist of liquid funds, which have been classified as Level 1 of the fair value hierarchy because they have been valued using quoted prices in active markets. The Company's cash and cash equivalents have also been classified as Level 1 on the same principle. Financial instruments are classified as current if they are expected to be liquidated within the next twelve months. The Company's remaining investments have been classified as Level 3 instruments as there is little or no market data. Level 3 investments are valued using the cost method.

The following table presents information about the Company's assets that are measured at fair value on a recurring basis as of June 30, 2025, and March 31, 2025, and indicates the fair value hierarchy of the valuation techniques the Company used to determine such fair value:

***(in thousands)***

*As of June 30, 2025*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Particular** | **Adjusted<br> Cost <br> ($)** | **Gain <br> ($)** | **Loss<br> ($)** | **Fair Value<br> ($)** | **Cash &<br> Cash<br> Equivalents<br> ($)** | **Short <br> Term<br> Investments<br> ($)** |
| **Level 1** | | | | | | |
| Cash | 163 |  |  | 163 | 163 |  |
| Money Market Fund |  |  |  |  |  |  |
| Debt Funds |  |  |  |  |  |  |
| Mutual Fund | - |  |  | - | - |  |
| **Level 2** |  |  |  |  |  |  |
| Certificates of Deposit | 291 |  |  | 291 | 291 |  |
| **Level 3** | **-** |  |  | **-** | - |  |
| **TOTAL** | **454** |  |  | **454** | **454** |  |

---

*As of March 31, 2025*

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Particular** | **Adjusted<br> Cost <br> ($)** | **Gain <br> ($)** | **Loss <br> ($)** | **Fair Value<br> ($)** | **Cash &<br> Cash<br> Equivalents<br> ($)** | **Short <br> Term<br> Investments<br> ($)** |
| **Level 1** | | | | | | |
| Cash | 368 |  |  | 368 | 368 |  |
| Money Market Fund |  |  |  |  |  |  |
| Debt Funds |  |  |  |  |  |  |
| Mutual Fund | - |  |  | - | - |  |
| **Level 2** |  |  |  |  |  |  |
| Certificates of Deposit | 37 |  |  | 37 | 37 |  |
| **Level 3** | - |  |  | - | - |  |
| **TOTAL** | **405** |  |  | **405** | **405** |  |

---

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**NOTE 16** – **SEGMENT INFORMATION**

FASB ASC 280, "*Segment Reporting,*" establishes standards for reporting information about reportable segments. Operating segments are defined as components of an enterprise about which separate financial information is available and is evaluated regularly by the chief operating decision maker, or decision-making group (CODM), in deciding how to allocate resources and in assessing performance. The CODM evaluates revenues and gross profits based on product lines and routes to market. The Company's CODM is the Company's Chief Executive Officer (CEO). The CEO reviews financial information presented on an operating segment basis for the purposes of making operating decisions and assessing financial performance. As of the date of this report and in preparation for the new and different source of revenue, the Company has determined that it operates in a single operating and reportable segment, Life Sciences segment.

The following provides information required by ASC 280-10-50-38 "Entity-wide Information":

1) The table below shows revenue reported by segment:

---

| | | |
|:---|:---|:---|
|  | ***(in thousands) <br> Three months ended <br> June 30,*** | ***(in thousands) <br> Three months ended <br> June 30,*** |
|  | **2025<br> ($)** | **2024<br> ($)** |
| **Life Sciences segment** |  |  |
| Wellness and lifestyle | 6 | 21 |
| White labeling services | 322 | 251 |
| **Total** | **328** | **272** |

---

For information on revenue by product and service, refer to Note 2, "Summary of Significant Accounting Policies".

2) The table below shows the revenue attributed to the country of domicile (U.S.) and foreign countries. Revenue is generally attributed to the geographic location of customers:

---

| | | | |
|:---|:---|:---|:---|
| | | **(in thousands)** | **(in thousands)** |
| <br>**Segments** |<br>**Country** | **Three months <br> ended <br> June 30, <br> 2025 <br> ($)** | **Percentage of <br> Total <br> Revenue <br> ($)** |
| Asia | India |  |  |
| America | U.S. | 328 | 100% |
|  | Colombia | - | - |
| Total |  | 328 | 100% |

---

---

| | | | |
|:---|:---|:---|:---|
| | | ***(in thousands)*** | ***(in thousands)*** |
| <br>**Segments** |<br>**Country** | **Three months<br> ended<br> June 30,<br> 2024 <br> ($)** | **Percentage of <br> Total<br> Revenue <br> ($)** |
| Asia | India |  |  |
| America | U.S. | 272 | 100% |
|  | Colombia | - | - |
| Total |  | **272** | **100%** |

---

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

3) The table below shows the non-current assets other than financial instruments held in the country of domicile and foreign countries.

---

| | | | |
|:---|:---|:---|:---|
|  | **(in thousands)** | **(in thousands)** | **(in thousands)** |
| **Nature of assets** | **USA <br> (Country <br> of Domicile)<br> ($)** | **Foreign<br> Countries<br> (India and<br> Colombia)<br> ($)** | **Total <br> as of <br> June 30, <br> 2025<br> ($)** |
| Intangible assets, net | 1997 |  | 1997 |
| Property, plant, and equipment, net | 3051 | 46 | 3097 |
| Claims and advances | 410 | 270 | 680 |
| Operating lease asset | - | 16 | 16 |
| **Total non-current assets** | **5458** | **332** | **5790** |

---

---

| | | | |
|:---|:---|:---|:---|
|  | ***(in thousands)*** | ***(in thousands)*** | ***(in thousands)*** |
| **Nature of assets** | **USA <br> (Country of<br> Domicile) <br> ($)** | **Foreign<br> Countries <br> (India and<br> Colombia) <br> ($)** | **Total<br> as of <br> March 31,<br> 2025 <br> ($)** |
| Intangible assets, net | 1852 |  | 1852 |
| Property, plant, and equipment, net | 3171 | 49 | 3220 |
| Claims and advances | 410 | 271 | 681 |
| Operating lease asset | 80 | 18 | 98 |
| **Total non-current assets** | **5513** | **338** | **5851** |

---

**NOTE 17** – **SUBSEQUENT EVENT**

Subsequent to the quarter through July 31, 2025, the Company sold 6,623,085 shares through the ATM for $2,623,467 at an average price of $0.41.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**Item 2. Management**'**s Discussion and Analysis of Financial Condition and Results of Operations**

The purpose of this Management's Discussion and Analysis (MD&A) is to provide an understanding of IGC Pharma, Inc.'s ("IGC," "IGC Pharma," the "Company," "we," "our," and/or "us") consolidated financial condition and results of operations and cash flows. The MD&A should be read in conjunction with our unaudited condensed financial statements and related notes that appear elsewhere in this Quarterly Report on Form 10-Q for the three months ended June 30, 2025, and the Annual Report on Form 10-K for the fiscal year ended March 31, 2025, filed with the SEC on June 27, 2025 (the 2025 Form 10-K). The Company's actual results could differ materially from those discussed here. Factors that could cause differences include those discussed in the "Forward-Looking Statements" and "Risk Factors" sections and discussed elsewhere in this report. The risks and uncertainties can cause actual results to differ significantly from those in our forward-looking statements or implied in historical results and trends. Accordingly, we caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as expressly required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those outlined in the forward-looking statements.

**Overview**

IGC Pharma, a clinical-stage pharmaceutical company developing treatments for Alzheimer's disease (AD) and related neurodegenerative conditions, is committed to transforming patient care by seeking to offer faster-acting and more effective solutions. The Company's research and development efforts are centered on addressing some of the most challenging and underserved symptoms of Alzheimer's, with the lead investigational candidate, IGC-AD1, positioned at the forefront of this strategy. It is designed to treat agitation in Alzheimer's dementia, a common and difficult-to-manage neuropsychiatric symptom that significantly impacts millions of patients' well-being and caregiver burden.

***Life Sciences Segment***

IGC Pharma, a clinical-stage company developing treatments for Alzheimer's disease, is committed to transforming patient care by striving to offer faster acting and more effective solutions. Our lead drug, IGC-AD1, embodies this vision by tackling a critical challenge – managing agitation in Alzheimer's dementia. Early results from our Phase 2 trial are promising: IGC-AD1 effectively reduced agitation in patients compared to a placebo, and crucially, it did so faster than traditional medications. While existing anti-psychotics can take as long 6 to 12 weeks to show effects, we believe IGC-AD1 has the potential to act within two weeks. This potentially faster onset of action could significantly improve patient care and represents a potential breakthrough in managing Alzheimer's-related agitation, although there can be no assurance thereof. In addition, we have created in-house wellness brands, available through online channels that are compliant with relevant federal, state, and local laws and regulations. We derive revenue from our in-house wellness non-pharmaceutical formulations that are manufactured as non-GMO, vegan, products at our facility and are sold over-the-counter (OTC).

**MINT-AD**

Currently, the AI team is working on developing a Multimodal Interpretable Transformer for Alzheimer's Disease (MINT-AD). This tool aims to support clinicians in real-world decision-making towards reducing Alzheimer's false negatives and delayed diagnosis. We are developing MINT-AD for three aims/phases: risk stratification for AD, cognitive decline prediction 2-5 years in advance, and deployment as a physician's tool.

According to the World Alzheimer Report, more than 400 million people globally may carry Alzheimer's-related pathology before any clinical symptoms appear. Yet primary care physicians, particularly those outside urban centers, often lack the tools needed to detect early cognitive risk. This diagnostic gap leads to missed or delayed diagnoses, limiting timely intervention, reducing eligibility for clinical trials, and ultimately worsening patient outcomes. MINT-AD aims to bridge this gap by extending cognitive diagnostics beyond neurology clinics, expensive PET scans, and other tests, to general practices, rural areas, and underserved populations.

MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories. The platform is being designed for integration into physician workflows to help improve early detection, care personalization, and clinical trial enrolment.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**Our Business Strategy**

The business strategy includes:

● Advance Differentiated Therapies for High-Need CNS Indications.

● Expand IGC-AD1's therapeutic potential to treat AD, subject to FDA approval.

● Advance the development of TGR-63 as a potential therapeutic for AD.

● Advance the development of TGR-63 as a potential therapeutic for AD.

● Publish scientific findings in peer-reviewed journals to strengthen clinical credibility and visibility.

● Allocate Capital to Enhance Shareholder Value.

We believe developing a drug for both symptom and disease-modifying agents has less risk due to the need for expensive multi-year trials. However, there is considerable upside and significant value creation to the extent we obtain a first-in-class advantage, of which there can be no assurance. If we were to obtain a first-in-class advantage, such an advantage could result in significant growth if and when an approved drug such as IGC-AD1 launches.

We believe that additional investment in clinical trials, AI, R&D, facilities, marketing, advertising, and the acquisition of complementary products and businesses will be critical to the ongoing growth of the Life Sciences segment. Although there can be no assurance, we believe these investments will fuel the development and delivery of innovative products that drive positive patient and customer experiences. We hope to leverage our R&D and intellectual property to develop ground-breaking, science-based products that are proven effective through clinical trials, subject to FDA approval. Although there can be no assurance, we believe this strategy can improve our existing products and lead to the creation of new products that can provide treatment options for multiple conditions, symptoms, and side effects.

Management is committed to its core short term goals, completion of the Phase 2 trial on IGC-AD1 and deploying MINT-AD. As we allocate more resources to achieving these objectives, we are evaluating various options for our non-core assets such as the manufacturing facility in Vancouver, including potential operational partnerships or alternative uses. As of the date of this filing, no definitive transaction has been finalized or has occurred. It could reduce our revenue.

**Company Highlights for the Quarter ended June 30, 2025**

● IGC Pharma presented compelling Genetic Toxicology Safety Data on the API in IGC-AD1 at the 2025 Genetic Toxicology Association Meeting, highlighting the safety profile of our lead compound – a crucial step for regulatory approvals.

● IGC Pharma expanded its network of clinical trial sites for the CALMA trial, adding multiple strategic locations across North America. These expansions included leading research institutions and sites in diverse geographic areas such as Ontario (Canada), Florida, Rhode Island, Puerto Rico, and Oklahoma. This strategic broadening of our clinical trial footprint is designed to accelerate patient enrollment, enhance access to diverse patient populations, and strengthen the overall robustness of our study.

● During the quarter ended June 30, 2025, the Company raised a gross amount of approximately $997 thousand through different private equity placement SPAs and the ATM.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**Results of Operations for the Three Months Ended June 30, 2025, and June 30, 2024** 

The historical results presented below are not necessarily indicative of the results that may be expected for any future period. The following table presents an overview of our results of operations for the three months ended June 30, 2025, and June 30, 2024:

***Statement of Operations (in thousands, unaudited)***

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended <br> June 30,** | **Three months ended <br> June 30,** | | |
|  | **2025<br> ($)** | **2024<br> ($)** |<br>**Change<br> ($)** |<br>**Percent <br> Change** |
| Revenue | 328 | 272 | 56 | 21% |
| Cost of revenue | (174) | (109) | (65) | 60% |
| **Gross profit** | **154** | **163** | **(9)** | **(6)%** |
| Selling, general and administrative expenses | (1208) | (1670) | 462 | (28)% |
| Research and development expenses | (851) | (889) | 38 | (4)% |
| **Operating loss** | **(1905)** | **(2396)** | **491** | **(20)%** |
| Other income, net | 306 | 18 | 288 | 1600% |
| **Loss before income taxes** | **(1599)** | **(2378)** | **779** | **(33)%** |
| Income tax expense/benefit | - | - | - | - |
| **Net loss** | **(1599)** | **(2378)** | **779** | **(33)%** |

---

*Revenue* – Revenue was approximately $328 thousand and $272 thousand for the three months ended June 30, 2025, and June 30, 2024, respectively. Revenue in both quarters was primarily derived from our Life Sciences segment, which involved providing white-label manufactured products and sales of holistic health care products, among others. Our core focus is on advancing IGC-AD1, completing the Phase 2 trial, and developing MINT-AD for the early diagnosis of Alzheimer's disease. In the future, our revenue from white label may not increase as we allocate more resources to expanding our core pharma-focused programs.

*Cost of revenue* – Cost of revenue amounted to approximately $174 thousand for the three months ended June 30, 2025, compared to $109 thousand in the three months ended June 30, 2024. This represents gross margins of 47% and 60%, respectively. The cost of revenue is primarily attributable to the cost of raw materials, labor, and other direct overheads required to produce our products and services in both segments. The slight decrease in gross margin is attributed to the Company's strategic efforts to develop new formulations using a broader range of active ingredients, which, while affecting margins in the short term, are expected to open new commercial avenues in the long term.

*Selling, General and Administrative expenses (SG&A)*– SG&A expenses primarily encompass various costs such as employee-related expenses, sales commissions, professional fees, legal fees, marketing expenses, other corporate expenses, allocated general overhead, provisions, depreciation, and write-offs related to doubtful accounts and advances. During the three months ended June 30, 2025, SG&A expenses decreased by approximately $462 thousand or 28% to approximately $1.2 million as compared to the three months ended June 30, 2024. This significant decline in SG&A expenses is attributable to the Company's focused efforts to optimize corporate-level operational efficiency by lowering employee–related costs due to headcount alignment and compensation restructuring, implementing better inventory management systems, and reducing spending on legal and professional services through more efficient vendor management. These optimizations allowed the Company to preserve capital and extend its operational runway while maintaining the infrastructure necessary to support clinical development and strategic initiatives.

*Research and Development expenses (R&D)*– R&D expenses were attributed to our Life Sciences segment. The R&D expenses decreased by approximately $38 thousand or 4% to approximately $851 thousand during the three months ended June 30, 2025, from approximately $889 thousand. The decrease is primarily due to a one-time non-cash expense of approximately $100 thousand in three months ended June 30, 2024. One-time expense adjusted, there is an increase in R&D expenses by $62 thousand. The R&D expenses are primarily attributed to the progression of Phase 2 trials on IGC-AD1 and preclinical studies on TGR-63, indicating the Company's dedication to advancing its product pipeline. As the development of TGR-63 and the Phase 2 trial on Alzheimer's gains momentum, the Company anticipates an increase in R&D expenses.

*Other income, net* – Other net income increased by approximately $288 thousand or 1,600% during the three months ended June 30, 2025. As a result, the total other income for the three months ended June 30, 2025, and 2024 is approximately $306 thousand and $18 thousand, respectively. Other income includes interest and rental income, dividend income, profit from the sale of assets, unrealized gains from investments, net income, and income from scrap sales. The primary reason for increase is a tax credit of approximately $263 thousand company received during three months ended June 30, 2025.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**Liquidity and Capital Resources**

Our sources of liquidity are cash and cash equivalents, funds raised through the ATM offering, cash flows from operations, short-term and long-term borrowings, and short-term liquidity arrangements. The Company continues to evaluate various financing sources and options to raise working capital to help fund current research and development programs and operations. The Company does not have any material long-term debt, capital lease obligations, or other long-term liabilities except as disclosed in this report. Please refer to Note 12, "Commitments and Contingencies," and Note 11, "Loans and Other Liabilities," in Item 1 of this report for further information on the Company's commitments and contractual obligations.

On June 30, 2023, (the Effective Date), the Company entered into a Master Loan and Security Agreement along with the General Banking Facility Letter (collectively called the "Credit Agreement") with O-Bank Co., Ltd., a banking corporation incorporated under the laws of Taiwan, as administrative agent and lender (the Lender) pursuant to which the Borrower may borrow up to $12 million only or the equivalent thereof in other major currencies (the Credit Facility). The Credit Facility under the Credit Agreement contained a maturity date on the first anniversary of the Effective Date. Borrowings under the Credit Agreement will bear interest, calculated according to the interest rate mentioned in the Certificate of Deposit, as the case may be, plus an applicable margin of 1%, and the Borrower shall bear the tax. Interest is due and payable in full by the Borrower on the last business day of each interest period.

On June 24, 2025, the Company entered into an amendment to extend the Credit Agreement. The amendment extends the term of the Credit Agreement, which was set to expire, under the same terms and conditions as previously disclosed, with the exception of i) a reduction in the facility fees from $84,000 to $48,000 and ii) interest, calculated according to the interest rate mentioned in the Certificate of Deposit, as the case may be, plus an applicable margin of 1.2%, instead of 1%. All other material terms of the Credit Agreement remain unchanged.

In the first quarter of Fiscal 2026, the Company entered into the 2025 Share Purchase Agreements (2025 SPAs) with multiple investors, relating to the sale and issuance by our company to the investors of an aggregate of 2,803,333 shares of our common stock, for a total purchase price of $841,000 , or $0.30 per share, subject to the terms and conditions set forth in the 2025 SPAs. The investments are subject to customary closing conditions, including NYSE approval. As per the 2025 SPA, the investor received piggyback registration rights subject to certain restrictions.

Subsequent to the quarter through July 31, 2025, the Company sold 6,623,085 shares through the ATM for $2,623,467 at an average price of $0.41.

The equity and the credit facility serve to minimize ongoing liquidity requirements and ensure the Company's ability to sustain its operations. Furthermore, the Company intends to raise additional funds through private placement and ATM offerings, subject to market conditions, although there can be no assurance that such financing efforts will be successful. The Company expects to raise further capital for its research and development initiatives as and when it is able to do so, in an ATM offering or private placement. In addition, there can be no assurance of the terms thereof, and any subsequent equity financing sought may have dilutive effects on our current shareholders. While there is no guarantee that we will be successful, we are applying to non-dilutive funding opportunities such as Small Business Research and Development programs. In addition, subject to limitations on the amount of capital that can be raised, the Company expects to utilize its shelf registration on a statement on Form S- 3 to raise capital through at-the-market offerings or otherwise. Please refer to Note 13 – "Securities", for more information.

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***(in thousands, unaudited)*** | ***(in thousands, unaudited)*** | | |
|  | **As of <br> June 30,<br> 2025<br> ($)** | **As of <br> March 31,<br> 2025<br> ($)** |<br>**Change** |<br>**Percent<br> Change** |
| Cash and cash equivalents | 454 | 405 | 49 | 12% |
| Working capital | 428 | 639 | (211) | (33)% |

---

*Cash and cash equivalents* 

Cash and cash equivalents increased by approximately $49 thousand to $454 thousand in the three months ended June 30, 2025, from $405 thousand as of March 31, 2025, an increase of approximately 12%.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

*Summary of Cash flows*

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | ***(in thousands, unaudited)*** | ***(in thousands, unaudited)*** | | |
|  | **Three months ended <br> June 30,** | **Three months ended <br> June 30,** | |<br>**Percent** |
|  | **2025** | **2024** | **Change** | **Change** |
| Cash used in operating activities | (1407) | (1752) | 345 | (20)% |
| Cash provided by (used in) investing activities | 580 | (131) | 711 | (543)% |
| Cash provided by financing activities | 851 | 2507 | (1656) | (66)% |
| Effects of exchange rate changes on cash and cash equivalents | 25 | 2 | 23 | 1150% |
| **Net decrease in cash and cash equivalents** | **49** | **626** | **(577)** | **(92)%** |
| Cash and cash equivalents at the beginning of the period | 405 | 1198 | (793) | (66)% |
| **Cash and cash equivalents at the end of the period** | **454** | **1824** | **(1370)** | **(75)%** |

---

*Operating Activities*

Net cash used in operating activities for the three months ended June 30, 2025, was approximately $1.4 million. It consists of a net loss of approximately $1.6 million, a positive impact on cash due to non-cash expenses of approximately $569 thousand, and a negative change in operating assets and liabilities of approximately $377 thousand. Non-cash expenses consist of an amortization and depreciation charge of approximately $141 thousand, stock-based expenses of approximately $452 thousand, and other non-cash items with a negative impact of approximately $24 thousand. In addition, changes in operating assets and liabilities had a negative impact of approximately $377 thousand on cash, of which a net negative impact of approximately $53 thousand is due to an increase in accounts receivables, and a negative impact of approximately $599 thousand is due to decrease in accrued and other liabilities, a positive impact of approximately $183 thousand is due to decrease in deposits and advances, a positive impact of approximately $51 thousand is due to increase in accounts payable and net other current assets and liabilities of approximately $41 thousand.

Net cash used in operating activities for the three months ended June 30, 2024, was approximately $1.8 million. It consists of a net loss of approximately $2.4 million, a positive impact on cash due to non-cash expenses of approximately $564 thousand, and a positive change in operating assets and liabilities of approximately $62 thousand. Non-cash expenses consist of an amortization and depreciation charge of approximately $162 thousand and stock-based expenses of approximately $402 thousand. In addition, changes in operating assets and liabilities had a positive impact of approximately $62 thousand on cash, of which a net negative impact of approximately $118 thousand is due to an increase in deposits and advances, and a positive impact of approximately $151 thousand is due to increase in accrued and other liabilities, and net other current assets and liabilities of approximately $29 thousand.

*Investing Activities*

Net cash provided by investing activities for the three months ended June 30, 2025, was approximately $580 thousand, which comprised of approximately $114 thousand for the acquisition and development of intangible assets, and approximately $693 thousand for the net purchase of property, plant, and equipment.

Net cash used in investing activities for the three months ended June 30, 2024, was approximately $131 thousand, which comprised of expenses of approximately $93 thousand for the acquisition and development of intangible assets, and approximately $38 thousand for the net purchase of property, plant, and equipment.

*Financing Activities*

Net cash provided by financing activities was approximately $851 thousand for the three months ended June 30, 2025, which was comprised of net proceeds from issuance of equity stock of approximately $852 thousand and re-payment of the loan of approximately $1 thousand. Please refer to Note 13 – "Securities", for more information.

Net cash provided by financing activities was approximately $2.5 million for the three months ended June 30, 2024, which was comprised of net proceeds from issuance of equity stock of approximately $2.5 million and re-payment of the loan of approximately $1 thousand. Please refer to Note 13 – "Securities", for more information.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**Treasury Strategy and Capital Allocation Considerations**

Management continually evaluates opportunities to optimize the Company's capital structure and enhance stockholders' equity while maintaining adequate liquidity to support operations. Since early 2024, we have assessed the potential use of digital assets, including bitcoin and other cryptocurrencies, as part of our treasury management strategy.

Subsequent to quarter-end, in September 2025, our management plans to invest a portion of its funds in digital assets, either directly or through ETPs that hold such assets. We believe that allocating a portion of our cash reserves to digital assets could diversify our treasury holdings, potentially enhance our balance sheet if the assets appreciate, and align with emerging best practices of certain public companies.

We expect to begin implementing this policy during the quarter ending September 30, 2025. The timing, size, and type of investments will be based on prevailing market conditions, liquidity needs, and risk management considerations. These investments involve material risks, as discussed in Item 1A – Risk Factors.

**Off-Balance Sheet Arrangements**

We do not have any outstanding derivative financial instruments, off-balance sheet guarantees, interest rate swap transactions, or foreign currency forward contracts. Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit, liquidity, or market risk support to such entity. We do not have any variable interest in an unconsolidated entity that provides financing, liquidity, market risk, or credit support to us or that engages in leasing, hedging, or research and development services with us.

**Critical Accounting Policies**

While all accounting policies impact financial statements, certain policies may be viewed as critical. Critical accounting policies are those that are both most important to the portrayal of financial condition and results of operations and that require management's most subjective or complex judgments and estimates. Our management believes that the following policy that falls within this category in addition to the policies on revenue recognition, inventory, accounts receivable, foreign currency translation, impairment of long-lived assets and investments, stock-based compensation, and cybersecurity:

**Digital Asset Investments**

The Company may invest in digital assets, such as bitcoin and other cryptocurrencies, either directly or through ETPs that hold such assets. Direct holdings of digital assets will be accounted for in accordance with ASC 350-60, Intangibles – Goodwill and Other – Crypto Assets, and measured at fair value with changes recognized in earnings, in accordance with ASU 2023-08. Holdings in ETPs will be accounted for as equity securities under ASC 321, Investments – Equity Securities, and measured at fair value with changes recognized in earnings. Fair value will be determined using quoted prices in active markets (Level 1 inputs).

For direct holdings of digital assets, the Company will present in the notes a roll-forward of activity, including the opening balance, additions, dispositions, gains and losses recognized during the period, and the ending balance, as well as any significant concentrations and restrictions.

Please see our disclosures in Note 2 – Summary of Significant Accounting Policies to the Notes to the Unaudited Condensed Consolidated Financial Statements in this report, in the Notes to the Audited Consolidated Financial Statements in the 2025 Form 10-K, as well as Item 7 – Management's Discussion and Analysis of Financial Condition and Results of Operations in the 2025 Form 10-K, for a discussion of all our critical and significant accounting policies.

**Recent Accounting Pronouncements**

Changes to U.S. GAAP are established by the Financial Accounting Standards Board (FASB) in the form of accounting standards updates (ASUs) to the FASB's Accounting Standards Codification. The Company considers the applicability and impact of all ASUs. Newly issued ASUs not listed are expected to have no impact on the Company's consolidated financial position and results of operations because either the ASU is not applicable, or the impact is expected to be immaterial. Recent accounting pronouncements that may apply to us are described in Note 2, "Significant Accounting Policies" to the Notes to the Unaudited Condensed Consolidated Financial Statements in this report and in the Notes to the Audited Consolidated Financial Statements in Part II of our 2025 Form 10-K.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**Item 3. Quantitative and Qualitative Disclosures about Market Risk**

Item 3 does not apply to us because we are a smaller reporting company.

**Item 4. Controls and Procedures**

***Evaluation of Disclosure Controls and Procedures***

Our Management maintains disclosure controls and procedures as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed in our reports filed or submitted under the Exchange Act is processed, recorded, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to Management, including our Chief Executive Officer (our principal executive officer) and Principal Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure.

Our Management, including the Chief Executive Officer and Principal Financial Officer, conducted an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this report. Based on this evaluation, our Chief Executive Officer and Principal Financial Officer concluded that our disclosure controls and procedures were effective in ensuring that the information required to be disclosed in the reports filed or submitted by us under the Exchange Act was recorded, processed, summarized and reported within the requisite time periods specified in SEC rules and forms and that such information was accumulated and communicated to our Management, including our Chief Executive Officer and Principal Financial Officer, as appropriate to allow for timely decisions regarding required disclosure.

***Changes in Internal Control over Financial Reporting***

Our Management, including our Chief Executive Officer and Principal Financial Officer, evaluated our "internal control over financial reporting" as defined in Exchange Act Rule 13a-15(f) to determine whether any changes in our internal control over financial reporting occurred during the three months ended June 30, 2025, that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Based on that evaluation, there were no changes in our internal control over financial reporting during the three months ended June 30, 2025, that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**PART II** – **OTHER INFORMATION**

**Item 1. Legal Proceedings**

The Company may be involved in legal proceedings, claims, and assessments arising in the ordinary course of business. Such matters are subject to many uncertainties, and outcomes are not predictable with assurance. As of June 30, 2025, we were not party to any material legal proceedings, except as set forth below.

During the quarter ended June 30, 2025, the following material litigation is pending:

**Engineering and Consulting Group SAS et al. v IGC Pharma Inc**., case file no. 110016000050202247710 (Prosecutor's Office 393 Sectional Economic Crimes Unit, Bogota, Colombia). The Company and the ECG corporation are in a contractual dispute. The Company filed a complaint against four (4) individuals with the Prosecutor's Office 393 Sectional Economic Crimes Unit, Bogota, Colombia, under file no. 110016000050202247710 for charges of fraud, falsification of a private document, and conspiracy to commit a crime. The complaint was filed in 2022. In December 2023, the case was reviewed by the investigator and scheduled and accepted for a hearing by the prosecutor in calendar 2024. During the three months ended June 30, 2025, there were no material changes.

**Item 1A. Risk Factors**

Following are the material changes to the risk factors disclosed in Part I, Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended March 31, 2025, filed with the SEC on June 27, 2025.

**Investment in Digital Assets Could Adversely Affect Our Financial Condition and Results of Operations**

Management is considering a treasury policy that permits the investment of a limited portion of our available funds in digital assets, such as bitcoin and other cryptocurrencies, either directly or through exchange-traded products ("ETPs") that hold such assets. We have not made any purchases as of the filing date of this Quarterly Report. Investments in digital assets are subject to significant risks and volatility:

● **Price Volatility:** The market prices of bitcoin, and other cryptocurrencies have historically been highly volatile and may be influenced by factors beyond our control, including market sentiment, macroeconomic conditions, changes in supply and demand, geopolitical events, regulatory developments, technological changes, and market disruptions. Large fluctuations in fair value could materially affect our reported earnings, financial position, and stock price.

● **Regulatory Risk:** Digital assets are a relatively new asset class and are subject to evolving U.S. federal, state, and foreign laws and regulations. Regulatory changes, or the interpretation or enforcement of existing laws, could restrict our ability to buy, sell, hold, or transact in digital assets and could adversely impact their value.

● **Custody and Operational Risk:** If we invest directly in digital assets, we will be exposed to operational and custody risks, including loss or theft of private keys, cybersecurity breaches, fraud, and insolvency of custodians. If we invest via ETPs, we will be subject to risks specific to those funds, including tracking errors relative to the underlying asset, reliance on the sponsor and custodian, and management fees.

● **Liquidity Risk:** The trading venues for digital assets and related products may experience outages, disruptions, or other operational issues that can impair our ability to transact, especially during times of market stress.

● **Tax and Accounting Impact:** Changes in U.S. tax law, including the Corporate Alternative Minimum Tax (CAMT), could cause us to incur tax liabilities on unrealized gains in digital assets. Accounting standards require us to record changes in fair value through earnings each reporting period, which may increase our earnings volatility.

There is no assurance that any investment in digital assets will result in a positive return, and we may incur losses that could adversely affect our business, financial condition, and results of operations.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds**

During the quarter ended June 30, 2025, the Company entered into Share Purchase Agreements (the 2025 SPAs) with multiple investors, relating to the sale and issuance by our company to investors of an aggregate of 2,803,333 shares of our common stock, for a total purchase price of $841,000, or $0.30 per share, subject to the terms and conditions set forth in the 2025 SPAs. The investments are subject to customary closing conditions, including NYSE approval. As per the 2025 SPAs, the investors received piggyback registration rights subject to certain restrictions. Shares are intended to be exempt from registration under the Securities Act by virtue of the provisions of Section 4 (a)(2) of the Securities Act.

**Item 3. Defaults Upon Senior Securities**

None.

**Item 4. Mine Safety Disclosures**

Not applicable.

**Item 5. Other Information**

None.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**Item 6. Exhibits**

---

| | |
|:---|:---|
| **Exhibit**<br>**Number** | <br>**Exhibit Description** |
| 3.1 | [Amended and Restated Articles of Incorporation of the Registrant, as amended on August 1, 2012 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on August 6, 2012).](http://www.sec.gov/Archives/edgar/data/1326205/000118518512001643/ex3-1.htm) |
| 3.2 | [Articles of Amendment to the Company's Amended and Restated Articles of Incorporation filed with the State Department of Assessments and Taxation of Maryland on March 7, 2023 (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K filed on March 21, 2023).](http://www.sec.gov/Archives/edgar/data/1326205/000118518523000238/ex_490458.htm) |
| 3.3 | [By-laws of the Registrant (incorporated by reference to Exhibit 3.2 to the Company's Post-Effective Amendment No.1 to Form S-3 filed on January 22, 2021).](http://www.sec.gov/Archives/edgar/data/1326205/000118518521000102/ex_222077.htm) |
| 3.4 | [Amendment to the Amended and Restated Articles of Incorporation of the Registrant as amended on August 2, 2014 (incorporated by reference to Exhibit 3.3 to the Company's Post-Effective Amendment No.1 to Form S-3 filed on January 22, 2021).](http://www.sec.gov/Archives/edgar/data/1326205/000118518521000102/ex_222078.htm) |
| 3.5 | [Amendment to the Bylaws of the Company dated March 2, 2023 (incorporated by reference to Exhibit 3.2 to the Company's Current Report on Form 8-K filed on March 21, 2023).](http://www.sec.gov/Archives/edgar/data/1326205/000118518523000238/ex_490459.htm) |
| 10.1 | [Extension of Master Loan Agreement between IGC Pharma, Inc. and O-Bank, CO., LTD.](igcex10-1.htm) |
| 31.1\* | [Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer.](igcex31-1.htm) |
| 31.2\* | [Rule 13a-14(a) / 15d-14(a) Certification of Principal Financial Officer.](igcex31-2.htm) |
| 32.1\*\* | [Certifications pursuant to 18 U.S.C. §1350.](igcex32-1.htm) |
| 101.INS\* | Inline XBRL Instance Document. |
| 101.SCH\* | Inline XBRL Taxonomy Extension Schema Document. |
| 101.CAL\* | Inline XBRL Taxonomy Extension Calculation Linkbase Document. |
| 101.LAB\* | Inline XBRL Taxonomy Extension Label Linkbase Document. |
| 101.PRE\* | Inline XBRL Taxonomy Extension Presentation Linkbase Document. |
| 101.DEF\* | Inline XBRL Taxonomy Extension Definition Linkbase Document. |
| 104\* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101) |

---

\* Filed herewith.

\*\* Furnished herewith.

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

[**Table of Contents**](#TableOfContents)

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **IGC PHARMA, INC.** | **IGC PHARMA, INC.** |
| Date: August 14, 2025 | By: | /s/ Ram Mukunda |
|  |  | Ram Mukunda |
|  |  | President and Chief Executive Officer<br> (Principal Executive Officer) |
| Date: August 14, 2025 | By: | /s/ Claudia Grimaldi |
|  |  | Claudia Grimaldi |
|  |  | Vice-president & Chief Compliance Officer<br> (Principal Financial Officer) |

---

---

| | |
|:---|:---|
| ![](image_002.jpg) | \| June 30, 2025, Form 10-Q |

---

## Exhibit 10.1

**Exhibit 10.1**

![](ex10-1_01.jpg)

![](ex10-1_02.jpg)

![](ex10-1_03.jpg)

![](ex10-1_04.jpg)

![](ex10-1_05.jpg)

![](ex10-1_06.jpg)

![](ex10-1_07.jpg)

![](ex10-1_08.jpg)

![](ex10-1_09.jpg)

![](ex10-1_10.jpg)

![](ex10-1_11.jpg)

![](ex10-1_12.jpg)

![](ex10-1_13.jpg)

![](ex10-1_14.jpg)

![](ex10-1_15.jpg)

![](ex10-1_16.jpg)

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 17 CFR 240.13(a)-14(a)**

**(SECTION 302 CERTIFICATION)**

I, Ram Mukunda, certify that:

1. I have reviewed this quarterly
report on Form 10-Q of IGC Pharma, Inc.;

2. Based on my knowledge, this
report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the
financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The Registrant's other
certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;a. Designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;b. Designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;c. Evaluated the effectiveness
of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;d. Disclosed in this report any
change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal
quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant's internal control over financial reporting; and

5. The Registrant's other
certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent
functions):

&nbsp;&nbsp;&nbsp;&nbsp;a. All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;b. Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: August 14, 2025 | By: | /s/ Ram Mukunda |
|  |  | Ram Mukunda |
|  |  | President and Chief Executive Officer<br> (Principal Executive Officer) |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 17 CFR 240.13(a)-14(a)**

**(SECTION 302 CERTIFICATION)**

I, Claudia Grimaldi, certify that:

1. I have reviewed this quarterly
report on Form 10-Q of IGC Pharma, Inc.;

2. Based on my knowledge, this
report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,
in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the
financial statements, and other financial information included in this report, fairly present in all material respects the financial
condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The Registrant's other
certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange
Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))
for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;a. Designed such disclosure controls
and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly
during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;b. Designed such internal control
over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance
with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;c. Evaluated the effectiveness
of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of
the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;d. Disclosed in this report any
change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal
quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably
likely to materially affect, the registrant's internal control over financial reporting; and

5. The Registrant's other
certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the
registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent
functions):

&nbsp;&nbsp;&nbsp;&nbsp;a. All significant deficiencies
and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely
affect the registrant's ability to record, process, summarize, and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;b. Any fraud, whether or not material,
that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | |
|:---|:---|:---|
| Date: August 14, 2025 | By: | /s/ Claudia Grimaldi |
|  |  | Claudia Grimaldi |
|  |  | Vice-president & Chief Compliance Officer<br> (Principal Financial Officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER**

**PURSUANT TO 18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

I, Ram Mukunda, certify, as of the date hereof, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of IGC Pharma, Inc. on Form 10-Q for the period ended June 30, 2025, (i) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) that information contained in such Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of IGC Pharma, Inc. at the dates and for the periods indicated.

---

| | | |
|:---|:---|:---|
| Date: August 14, 2025 | By: | /s/ Ram Mukunda |
|  |  | Ram Mukunda |
|  |  | Chief Executive Officer and President<br> (Principal Executive Officer) |

---

I, Claudia Grimaldi, certify, as of the date hereof, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of IGC Pharma, Inc. on Form 10-Q for the period ended June 30, 2025, (i) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) that information contained in such Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of IGC Pharma, Inc. at the dates and for the periods indicated.

---

| | | |
|:---|:---|:---|
| Date: August 14, 2025 | By: | /s/ Claudia Grimaldi |
|  |  | Claudia Grimaldi |
|  |  | Vice-president & Chief Compliance Officer<br> (Principal Financial Officer) |

---